Whole-Body Imaging Modalities in Oncology

ABSTRACT

This article outlines the expanding approaches to whole-body imaging in oncology focusing on whole-body MRI and comparing it to emerging applications of whole-body CT, scintigraphy, and above all PET CT imaging. Whole-body MRI is widely available, non-ionizing and rapidly acquired, and inexpensive relative to PET CT. While it has many advantages, WBMRI is non-specific and, when compared to PET CT, is less sensitive. This article expands each of these issues comparing individual modalities as they refer to specific cancers.

KEYWORDS

WBMRI - whole-body CT - PETCT - oncology

REFERENCES

• 1 Kapoor V, McCook B M, Torok F S. An introduction to PET-CT imaging.  Radiographics. 2004;  24(2) 523-543
• 2 Kauhanen S P, Komar G, Seppänen M P et al.. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.  Ann Surg. 2009;  250(6) 957-963
• 3 Nam E J, Yun M J, Oh Y T et al.. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US and CT or MRI.  Gynecol Oncol. 2009; 
• 4 Antoch G, Vogt F M, Freudenberg L S et al.. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology.  JAMA. 2003;  290(24) 3199-3206
• 5 Czernin J, Allen-Auerbach M, Schelbert H R. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006.  J Nucl Med. 2007;  48(suppl 1) 78S-88S
• 6 Hillner B E, Siegel B A, Liu D et al.. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.  J Clin Oncol. 2008;  26(13) 2155-2161
• 7 Mawlawi O, Townsend D W. Multimodality imaging: an update on PET/CT technology.  Eur J Nucl Med Mol Imaging. 2009;  36(suppl 1) S15-S29
• 8 Nanni C, Rubello D, Castellucci P et al.. Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients.  Eur J Nucl Med Mol Imaging. 2005;  32(5) 589-592
• 9 Blodgett T M, Meltzer C C, Townsend D W. PET/CT: form and function.  Radiology. 2007;  242(2) 360-385
• 10 Poeppel T D, Krause B J, Heusner T A, Boy C, Bockisch A, Antoch G. PET/CT for the staging and follow-up of patients with malignancies.  Eur J Radiol. 2009;  70(3) 382-392
• 11 Hoh C K. Clinical use of FDG PET.  Nucl Med Biol. 2007;  34(7) 737-742
• 12 Marklund M, Christensen R, Torp-Pedersen S, Thomsen C, Nolsøe C P. Signal intensity of normal breast tissue at MR mammography on midfield: applying a random coefficient model evaluating the effect of doubling the contrast dose.  Eur J Radiol. 2009;  69(1) 93-101
• 13 Goo H W, Choi S H, Ghim T, Moon H N, Seo J J. Whole-body MRI of paediatric malignant tumours: comparison with conventional oncological imaging methods.  Pediatr Radiol. 2005;  35(8) 766-773
• 14 Eustace S J, Nelson E. Whole body magnetic resonance imaging.  BMJ. 2004;  328(7453) 1387-1388
• 15 Eustace S, Tello R, DeCarvalho V et al.. A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases.  AJR Am J Roentgenol. 1997;  169(6) 1655-1661
• 16 Johnston C, Brennan S, Ford S, Eustace S. Whole body MR imaging: applications in oncology.  Eur J Surg Oncol. 2006;  32(3) 239-246
• 17 Schmidt G P, Reiser M F, Baur-Melnyk A. Whole-body MRI for the staging and follow-up of patients with metastasis.  Eur J Radiol. 2009;  70(3) 393-400
• 18 Schmidt G P, Baur-Melnyk A, Herzog P et al.. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system.  Invest Radiol. 2005;  40(12) 743-753
• 19 O'Connell M J, Hargaden G, Powell T, Eustace S J. Whole-body turbo short tau inversion recovery MR imaging using a moving tabletop.  AJR Am J Roentgenol. 2002;  179(4) 866-868
• 20 Hopper K D, Singapuri K, Finkel A. Body CT and oncologic imaging.  Radiology. 2000;  215(1) 27-40
• 21 Poitout D, Gaujoux G, Lempidakis M et al.. X-ray computed tomography or MRI in the assessment of bone tumor extension [in French].  Chirurgie. 1991;  117(5–6) 488-490
• 22 Schmidt G P, Reiser M F, Baur-Melnyk A. Whole-body imaging of the musculoskeletal system: the value of MR imaging.  Skeletal Radiol. 2007;  36(12) 1109-1119
• 23 Lardinois D, Weder W, Hany T F et al.. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.  N Engl J Med. 2003;  348(25) 2500-2507
• 24 Plathow C, Aschoff P, Lichy M P et al.. Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer—initial results.  Invest Radiol. 2008;  43(5) 290-297
• 25 Ohno Y, Koyama H, Onishi Y et al.. Non-small cell lung cancer: whole-body MR examination for M-stage assessment—utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.  Radiology. 2008;  248(2) 643-654
• 26 Rendina E A, Bognolo D A, Mineo T C et al.. Computed tomography for the evaluation of intrathoracic invasion by lung cancer.  J Thorac Cardiovasc Surg. 1987;  94(1) 57-63
• 27 Buy J N, Ghossain M A, Poirson F et al.. Computed tomography of mediastinal lymph nodes in nonsmall cell lung cancer. A new approach based on the lymphatic pathway of tumor spread.  J Comput Assist Tomogr. 1988;  12(4) 545-552
• 28 Marom E M, McAdams H P, Erasmus J J et al.. Staging non-small cell lung cancer with whole-body PET.  Radiology. 1999;  212(3) 803-809
• 29 Mac Manus M P, Hicks R J, Matthews J P et al.. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer.  J Clin Oncol. 2003;  21(7) 1285-1292
• 30 Goerres G W, von Schulthess G K, Steinert H C. Why most PET of lung and head-and-neck cancer will be PET/CT.  J Nucl Med. 2004;  45(suppl 1) 66S-71S
• 31 Mukherji S K, Bradford C R. Controversies: is there a role for positron-emission tomographic CT in the initial staging of head and neck squamous cell carcinoma?.  AJNR Am J Neuroradiol. 2006;  27(2) 243-245
• 32 Malone J P, Gerberi M A, Vasireddy S et al.. Early prediction of response to chemoradiotherapy for head and neck cancer: reliability of restaging with combined positron emission tomography and computed tomography.  Arch Otolaryngol Head Neck Surg. 2009;  135(11) 1119-1125
• 33 Shah G V, Wesolowski J R, Ansari S A, Mukherji S K. New directions in head and neck imaging.  J Surg Oncol. 2008;  97(8) 644-648
• 34 Ryan W R, Fee Jr W E, Le Q T, Pinto H A. Positron-emission tomography for surveillance of head and neck cancer.  Laryngoscope. 2005;  115(4) 645-650
• 35 Quon A, Fischbein N J, McDougall I R et al.. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma.  J Nucl Med. 2007;  48(suppl 1) 58S-67S
• 36 Schöder H, Yeung H W. Positron emission imaging of head and neck cancer, including thyroid carcinoma.  Semin Nucl Med. 2004;  34(3) 180-197
• 37 Merritt R M, Williams M F, James T H, Porubsky E S. Detection of cervical metastasis. A meta-analysis comparing computed tomography with physical examination.  Arch Otolaryngol Head Neck Surg. 1997;  123(2) 149-152
• 38 Imhof H, Czerny C, Dirisamer A. Head and neck imaging with MDCT.  Eur J Radiol. 2003;  45(suppl 1) S23-S31
• 39 Velázquez R A, McGuff H S, Sycamore D, Miller F R. The role of computed tomographic scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy.  Arch Otolaryngol Head Neck Surg. 2004;  130(1) 74-77
• 40 Hicks R J, Mac Manus M P, Seymour J F. Initial staging of lymphoma with positron emission tomography and computed tomography.  Semin Nucl Med. 2005;  35(3) 165-175
• 41 Reske S N. PET and restaging of malignant lymphoma including residual masses and relapse.  Eur J Nucl Med Mol Imaging. 2003;  30(suppl 1) S89-S96
• 42 La Fougère C, Hundt W, Bröckel N et al.. Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma.  Eur J Nucl Med Mol Imaging. 2006;  33(12) 1417-1425
• 43 Freudenberg L S, Antoch G, Schütt P et al.. FDG-PET/CT in re-staging of patients with lymphoma.  Eur J Nucl Med Mol Imaging. 2004;  31(3) 325-329
• 44 Tatsumi M, Cohade C, Nakamoto Y, Fishman E K, Wahl R L. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience.  Radiology. 2005;  237(3) 1038-1045
• 45 Mikhaeel N G, Hutchings M, Fields P A, O'Doherty M J, Timothy A R. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.  Ann Oncol. 2005;  16(9) 1514-1523
• 46 Hutchings M, Mikhaeel N G, Fields P A, Nunan T, Timothy A R. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.  Ann Oncol. 2005;  16(7) 1160-1168
• 47 Kellenberger C J, Miller S F, Khan M, Gilday D L, Weitzman S, Babyn P S. Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children.  Eur Radiol. 2004;  14(10) 1829-1841
• 48 Ribrag V, Vanel D, Leboulleux S et al.. Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy.  Eur J Radiol. 2008;  66(2) 325-331
• 49 Radford J A, Cowan R A, Flanagan M et al.. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease.  J Clin Oncol. 1988;  6(6) 940-946
• 50 Surbone A, Longo D L, DeVita Jr V T et al.. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.  J Clin Oncol. 1988;  6(12) 1832-1837
• 51 Guppy A E, Tebbutt N C, Norman A, Cunningham D. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma.  Leuk Lymphoma. 2003;  44(1) 123-125
• 52 Lavayssière R, Cabée A E, Filmont J E. Positron emission tomography (PET) and breast cancer in clinical practice.  Eur J Radiol. 2009;  69(1) 50-58
• 53 Heusner T A, Kuemmel S, Umutlu L et al.. Breast cancer staging in a single session: whole-body PET/CT mammography.  J Nucl Med. 2008;  49(8) 1215-1222
• 54 Choi J H, Lim H I, Lee S K et al.. The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging.  J Surg Oncol. 2009; 
• 55 Fuster D, Duch J, Paredes P et al.. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.  J Clin Oncol. 2008;  26(29) 4746-4751
• 56 Schmidt G P, Baur-Melnyk A, Haug A et al.. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.  Eur J Radiol. 2008;  65(1) 47-58
• 57 Engelhard K, Hollenbach H P, Wohlfart K, von Imhoff E, Fellner F A. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer.  Eur Radiol. 2004;  14(1) 99-105
• 58 Horvath L J, Burtness B A, McCarthy S, Johnson K M. Total-body echo-planar MR imaging in the staging of breast cancer: comparison with conventional methods—early experience.  Radiology. 1999;  211(1) 119-128
• 59 Izzo L, Stasolla A, Basso L et al.. Characterization of tumoral lesions of the breast: preliminary experience with multislice spiral CT.  J Exp Clin Cancer Res. 2005;  24(2) 209-215
• 60 Heusner T A, Kuemmel S, Hahn S et al.. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.  Eur J Nucl Med Mol Imaging. 2009;  36(10) 1543-1550
• 61 Lindfors K K, Meyer J E, Busse P M, Kopans D B, Munzenrider J E, Sawicka J M. CT evaluation of local and regional breast cancer recurrence.  AJR Am J Roentgenol. 1985;  145(4) 833-837
• 62 Dimopoulos M A, Moulopoulos L A, Terpos E. A new pet for myeloma.  Blood. 2009;  114(10) 2007-2008
• 63 Fonti R, Salvatore B, Quarantelli M et al.. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.  J Nucl Med. 2008;  49(2) 195-200
• 64 Zamagni E, Nanni C, Patriarca F et al.. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.  Haematologica. 2007;  92(1) 50-55
• 65 Ghanem N, Lohrmann C, Engelhardt M et al.. Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey.  Eur Radiol. 2006;  16(5) 1005-1014
• 66 Baur-Melnyk A, Buhmann S, Becker C et al.. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma.  AJR Am J Roentgenol. 2008;  190(4) 1097-1104
• 67 Lütje S, de Rooy J W, Croockewit S, Koedam E, Oyen W J, Raymakers R A. Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma.  Ann Hematol. 2009;  88(12) 1161-1168
• 68 Nanni C, Zamagni E, Farsad M et al.. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.  Eur J Nucl Med Mol Imaging. 2006;  33(5) 525-531
• 69 Lee I H, Choe Y H, Lee K H, Jeon E S, Choi J H. Comparison of multidetector CT with F-18-FDG-PET and SPECT in the assessment of myocardial viability in patients with myocardial infarction: a preliminary study.  Eur J Radiol. 2009;  72(3) 401-405
• 70 Moulopoulos L A, Gika D, Anagnostopoulos A et al.. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma.  Ann Oncol. 2005;  16(11) 1824-1828
• 71 Hillengass J, Wasser K, Delorme S et al.. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.  Clin Cancer Res. 2007;  13(2 Pt 1) 475-481
• 72 Gleeson T G, Moriarty J, Shortt C P et al.. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI).  Skeletal Radiol. 2009;  38(3) 225-236
• 73 Lowe V J, Booya F, Fletcher J G et al.. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer.  Mol Imaging Biol. 2005;  7(6) 422-430
• 74 Hsu W H, Hsu P K, Wang S J et al.. Positron emission tomography-computed tomography in predicting locoregional invasion in esophageal squamous cell carcinoma.  Ann Thorac Surg. 2009;  87(5) 1564-1568
• 75 Bruzzi J F, Munden R F, Truong M T et al.. PET/CT of esophageal cancer: its role in clinical management.  Radiographics. 2007;  27(6) 1635-1652
• 76 Bruzzi J F, Swisher S G, Truong M T et al.. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.  Cancer. 2007;  109(1) 125-134
• 77 Erasmus J J, Munden R F, Truong M T et al.. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging.  J Thorac Oncol. 2006;  1(5) 478-486
• 78 Javeri H, Xiao L, Rohren E et al.. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma.  Cancer. 2009;  115(22) 5184-5192
• 79 Shin S S, Jeong Y Y, Min J J, Kim H R, Chung T W, Kang H K. Preoperative staging of colorectal cancer: CT vs. integrated FDG PET/CT.  Abdom Imaging. 2008;  33(3) 270-277
• 80 Gollub M J, Akhurst T, Markowitz A J et al.. Combined CT colonography and 18F-FDG PET of colon polyps: potential technique for selective detection of cancer and precancerous lesions.  AJR Am J Roentgenol. 2007;  188(1) 130-138
• 81 Mainenti P P, Salvatore B, D'Antonio D et al.. PET/CT colonography in patients with colorectal polyps: a feasibility study.  Eur J Nucl Med Mol Imaging. 2007;  34(10) 1594-1603
• 82 Kitajima K, Murakami K, Yamasaki E et al.. Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT.  Eur J Nucl Med Mol Imaging. 2009;  36(9) 1388-1396
• 83 Squillaci E, Manenti G, Mancino S et al.. Staging of colon cancer: whole-body MRI vs. whole-body PET-CT—initial clinical experience.  Abdom Imaging. 2008;  33(6) 676-688
• 84 Sakurada A, Takahara T, Kwee T C et al.. Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer.  Eur Radiol. 2009;  19(6) 1461-1469
• 85 Schöder H, Larson S M, Yeung H W. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies.  J Nucl Med. 2004;  45(suppl 1) 72S-81S
• 86 Furukawa H, Ikuma H, Seki A et al.. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer.  Gut. 2006;  55(7) 1007-1011
• 87 Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy.  Eur Urol. 1999;  36(1) 31-35
• 88 Effert P J, Bares R, Handt S, Wolff J M, Büll U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose.  J Urol. 1996;  155(3) 994-998
• 89 Shreve P D, Grossman H B, Gross M D, Wahl R L. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.  Radiology. 1996;  199(3) 751-756
• 90 Seltzer M A, Barbaric Z, Belldegrun A et al.. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer.  J Urol. 1999;  162(4) 1322-1328
• 91 Schmid D T, John H, Zweifel R et al.. Fluorocholine PET/CT in patients with prostate cancer: initial experience.  Radiology. 2005;  235(2) 623-628
• 92 Reske S N, Deisenhofer S. Is 3′-deoxy-3′-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?.  Eur J Nucl Med Mol Imaging. 2006;  33(suppl 1) 38-43
• 93 Scher B, Seitz M, Albinger W et al.. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer.  Eur J Nucl Med Mol Imaging. 2007;  34(1) 45-53
• 94 Eschmann S M, Pfannenberg A C, Rieger A et al.. Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer.  Nucl Med (Stuttg). 2007;  46(5) 161-168; quiz N47–N48
• 95 Engeler C E, Wasserman N F, Zhang G. Preoperative assessment of prostatic carcinoma by computerized tomography. Weaknesses and new perspectives.  Urology. 1992;  40(4) 346-350
• 96 Pfannenberg C, Aschoff P, Schanz S et al.. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma.  Eur J Cancer. 2007;  43(3) 557-564
• 97 Strobel K, Dummer R, Steinert H C et al.. Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B.  Eur J Nucl Med Mol Imaging. 2008;  35(10) 1786-1795
• 98 Müller-Horvat C, Radny P, Eigentler T K et al.. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma.  Eur J Cancer. 2006;  42(3) 342-350
• 99 Holder Jr W D, White Jr R L, Zuger J H, Easton Jr E J, Greene F L. Effectiveness of positron emission tomography for the detection of melanoma metastases.  Ann Surg. 1998;  227(5) 764-769; discussion 769–771
• 100 Swetter S M, Carroll L A, Johnson D L, Segall G M. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients.  Ann Surg Oncol. 2002;  9(7) 646-653
• 101 Lauenstein T C, Semelka R C. Emerging techniques: whole-body screening and staging with MRI.  J Magn Reson Imaging. 2006;  24(3) 489-498
• 102 Morin S H, Cobbold J F, Lim A K et al.. Incidental findings in healthy control research subjects using whole-body MRI.  Eur J Radiol. 2009;  72(3) 529-533
• 103 Goehde S C, Hunold P, Vogt F M et al.. Full-body cardiovascular and tumor MRI for early detection of disease: feasibility and initial experience in 298 subjects.  AJR Am J Roentgenol. 2005;  184(2) 598-611
• 104 Brenner D J, Elliston C D. Estimated radiation risks potentially associated with full-body CT screening.  Radiology. 2004;  232(3) 735-738
• 105 Furtado C D, Aguirre D A, Sirlin C B et al.. Whole-body CT screening: spectrum of findings and recommendations in 1192 patients.  Radiology. 2005;  237(2) 385-394
• 106 Obuchowski N A, Holden D, Modic M T et al.. Total-body screening: preliminary results of a pilot randomized controlled trial.  J Am Coll Radiol. 2007;  4(9) 604-611
• 107 Beinfeld M T, Wittenberg E, Gazelle G S. Cost-effectiveness of whole-body CT screening.  Radiology. 2005;  234(2) 415-422
• 108 Schöder H, Gönen M. Screening for cancer with PET and PET/CT: potential and limitations.  J Nucl Med. 2007;  48(suppl 1) 4S-18S
• 109 Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging?.  Eur J Nucl Med Mol Imaging. 2009;  36(suppl 1) S113-S120
• 110 Frericks B B, Meyer B C, Martus P, Wendt M, Wolf K J, Wacker F. MRI of the thorax during whole-body MRI: evaluation of different MR sequences and comparison to thoracic multidetector computed tomography (MDCT).  J Magn Reson Imaging. 2008;  27(3) 538-545
• 111 Lichy M P, Aschoff P, Plathow C et al.. Tumor detection by diffusion-weighted MRI and ADC-mapping—initial clinical experiences in comparison to PET-CT.  Invest Radiol. 2007;  42(9) 605-613
• 112 Mürtz P, Krautmacher C, Träber F, Gieseke J, Schild H H, Willinek W A. Diffusion-weighted whole-body MR imaging with background body signal suppression: a feasibility study at 3.0 Tesla.  Eur Radiol. 2007;  17(12) 3031-3037
• 113 Rappeport E D, Loft A, Berthelsen A K et al.. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation.  Acta Radiol. 2007;  48(4) 369-378